/MTRY

MTRY Stock - Monterey Bio Acquisition Corporation

Q: What is the analyst price target for MTRY?

Analyst price target information is not currently available for MTRY.

Q: What is MTRY's market cap?

Market capitalization information is not currently available for MTRY.

Financial Services|Shell Companies|NASDAQ

$11.14-0.27%

$0.03 (-0.27%) • Nov 20

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $12.25

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MTRY

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.00

52W High$12.00

52W Low$10.21

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A
Gross Profit	$-2,039,000	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-2,039,000	$-523,000	$-2.4
Net Income	$-1,274,000	$-581,000	$-2.4
Net Margin	N/A	N/A	N/A
EPS	$-0.44	$-0.04	$-0.00

Company Overview

Monterey Bio Acquisition Corporation does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp. and changed its name to Monterey Bio Acquisition Corporation in April 2021. Monterey Bio Acquisition Corporation was incorporated in 2020 and is based in New York, New York.

Visit Website

Earnings History & Surprises

MTRY

Beat Rate

Last 0 quarters

Avg Surprise

+0%

EPS vs Estimate

Beats / Misses

0/0

Last 12 quarters

Latest EPS

$-0.03

Q2 2023

EPS Surprise History

Q4 22

No data

Q1 23

No data

Q2 23

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2023	Jun 30, 2023	—	$-0.03	—	—
Q1 2023	Mar 31, 2023	—	$-0.03	—	—
Q4 2022	Dec 31, 2022	—	$-0.11	—	—

Frequently Asked Questions about MTRY

What is MTRY's current stock price?

Monterey Bio Acquisition Corporation (MTRY) is currently trading at $11.14 per share. The stock has moved -0.27% today.

What is the analyst price target for MTRY?

No analyst price targets are currently available for this stock.

What sector is Monterey Bio Acquisition Corporation in?

Monterey Bio Acquisition Corporation operates in the Financial Services sector, specifically within the Shell Companies industry. The company is traded on the NASDAQ exchange.

What is MTRY's market cap?

Monterey Bio Acquisition Corporation has a market capitalization of $0.05 billion, making it a small-cap company.

Does MTRY pay dividends?

No, Monterey Bio Acquisition Corporation does not currently pay a dividend to shareholders.